

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **SUPPLEMENTAL ANNOUNCEMENT**

### **RESTRUCTURING OF SUZHOU FIRST PHARMA**

Reference is made to the announcement of the Company dated 1 September 2023 (the “**Announcement**”). Unless otherwise stated, terms defined in the Announcement shall have the same meanings when used in this announcement.

As disclosed in the Announcement, the Company intends to apply the net proceeds from the Placing as follows:

- (i) approximately HK\$11.4 million or 50.0% of the net proceeds from the Placing towards business development of the Group; and
- (ii) approximately HK\$11.4 million or 50.0% of the net proceeds from the Placing towards the working capital of the Group to support its business operations.

### **BUSINESS DEVELOPMENT**

Commencing in 2023, the Group has strategically redirected its primary focus and allocated resources towards establishing itself as a leading “Professional Bone Disease Treatment and Management Platform (骨健康全程治療與管理平台)”. This strategic shift will capitalize on the Group’s core capabilities and resources, allowing it to cater to the entire spectrum of bone-related healthcare needs with utmost professionalism and expertise. For further details of the Group’s business development, please refer to the supplemental announcement in relation to the restructuring of Suzhou First Pharma published by the Company on 14 September 2023.

## USE OF PROCEEDS

The Company intends to apply the net proceeds from the Placing in the following manner during the period from October to December 2023:

	<b>Amount of net proceeds from the Placing HK\$'000</b>
<b>Business development</b>	
For the pharmaceutical license for the purchase of orthopaedic drugs	5,000
For the processing fee to produce orthopaedic drugs under the pharmaceutical license	2,000
For the development of bone health products	1,500
For the capital of the research and development of Orticumab	2,900
	<hr/>
	11,400
	<hr/> <hr/>
<b>Working capital</b>	
Service fees for professional parties	4,900
Office rental and utilities expenses	800
Directors' emoluments and staff salaries	3,400
Other general expenses	2,300
	<hr/>
	11,400
	<hr/> <hr/>

**Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China NT Pharma Group Company Limited**  
**NG Tit**  
*Chairman*

Hong Kong, 14 September 2023

*As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Chin Yu; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.*